225 related articles for article (PubMed ID: 33184267)
1. Engineering of α-PD-1 antibody-expressing long-lived plasma cells by CRISPR/Cas9-mediated targeted gene integration.
Luo B; Zhan Y; Luo M; Dong H; Liu J; Lin Y; Zhang J; Wang G; Verhoeyen E; Zhang Y; Zhang H
Cell Death Dis; 2020 Nov; 11(11):973. PubMed ID: 33184267
[TBL] [Abstract][Full Text] [Related]
2. Cas9-edited immune checkpoint blockade PD-1 DNA polyaptamer hydrogel for cancer immunotherapy.
Lee J; Le QV; Yang G; Oh YK
Biomaterials; 2019 Oct; 218():119359. PubMed ID: 31349094
[TBL] [Abstract][Full Text] [Related]
3. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
4. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade augments humoral immunity through ICOS-mediated CD4
Zhang M; Xia L; Yang Y; Liu S; Ji P; Wang S; Chen Y; Liu Z; Zhang Y; Lu S; Wang Y
Int Immunopharmacol; 2019 Jan; 66():127-138. PubMed ID: 30448635
[TBL] [Abstract][Full Text] [Related]
6. Factors That Govern the Induction of Long-Lived Antibody Responses.
Chackerian B; Peabody DS
Viruses; 2020 Jan; 12(1):. PubMed ID: 31936163
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
9. Long-Lived Plasma Cells Secrete High-Affinity Antibodies Responding to a T-Dependent Immunization in a Teleost Fish.
Wu L; Fu S; Yin X; Guo Z; Wang A; Ye J
Front Immunol; 2019; 10():2324. PubMed ID: 31632403
[TBL] [Abstract][Full Text] [Related]
10. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors.
Seifert AM; Zeng S; Zhang JQ; Kim TS; Cohen NA; Beckman MJ; Medina BD; Maltbaek JH; Loo JK; Crawley MH; Rossi F; Besmer P; Antonescu CR; DeMatteo RP
Clin Cancer Res; 2017 Jan; 23(2):454-465. PubMed ID: 27470968
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Anti-PD-1 Antibody REGN2810 and Its Antitumor Activity in Human
Burova E; Hermann A; Waite J; Potocky T; Lai V; Hong S; Liu M; Allbritton O; Woodruff A; Wu Q; D'Orvilliers A; Garnova E; Rafique A; Poueymirou W; Martin J; Huang T; Skokos D; Kantrowitz J; Popke J; Mohrs M; MacDonald D; Ioffe E; Olson W; Lowy I; Murphy A; Thurston G
Mol Cancer Ther; 2017 May; 16(5):861-870. PubMed ID: 28265006
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman J; Moore EC; Zolkind P; Robbins Y; Clavijo PE; Sun L; Greene S; Morisada MV; Mydlarz WK; Schmitt N; Hodge JW; Schreiber H; Van Waes C; Uppaluri R; Allen C
Clin Cancer Res; 2020 Feb; 26(3):679-689. PubMed ID: 31645352
[TBL] [Abstract][Full Text] [Related]
14. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.
Wang C; Thudium KB; Han M; Wang XT; Huang H; Feingersh D; Garcia C; Wu Y; Kuhne M; Srinivasan M; Singh S; Wong S; Garner N; Leblanc H; Bunch RT; Blanset D; Selby MJ; Korman AJ
Cancer Immunol Res; 2014 Sep; 2(9):846-56. PubMed ID: 24872026
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
17. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes.
Luo XM; Maarschalk E; O'Connell RM; Wang P; Yang L; Baltimore D
Blood; 2009 Feb; 113(7):1422-31. PubMed ID: 19059876
[TBL] [Abstract][Full Text] [Related]
18. Engineering PD-1-Presenting Platelets for Cancer Immunotherapy.
Zhang X; Wang J; Chen Z; Hu Q; Wang C; Yan J; Dotti G; Huang P; Gu Z
Nano Lett; 2018 Sep; 18(9):5716-5725. PubMed ID: 30063143
[TBL] [Abstract][Full Text] [Related]
19. Splenic Long-Lived Plasma Cells Promote the Development of Follicular Helper T Cells during Autoimmune Responses.
Jang E; Cho WS; Oh YK; Cho ML; Kim JM; Paik DJ; Youn J
J Immunol; 2016 Feb; 196(3):1026-35. PubMed ID: 26729802
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model.
Suarez ER; Chang de K; Sun J; Sui J; Freeman GJ; Signoretti S; Zhu Q; Marasco WA
Oncotarget; 2016 Jun; 7(23):34341-55. PubMed ID: 27145284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
